{
  "id" : "lymphoma_ocular_adnexa",
  "algorithm" : "eod_public",
  "version" : "3.3",
  "name" : "Lymphoma Ocular Adnexa",
  "title" : "Lymphoma Ocular Adnexa",
  "notes" : "9590-9699, 9702-9719, 9725-9726, 9734-9738, 9823, 9826-9827, 9930 (C441, C690, C695-C696)\n\n**Note 1:** **Sources used in the development of this schema**\n* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)\n* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)\n* Collaborative Stage Data Collection System, version 02.05:  https://cancerstaging.org/cstage/Pages/default.aspx \n* Chapter 71 *Ocular Adnexal Lymphoma*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.\n\n**Note 2:** **Origination of Ocular Adnexal Lymphomas** \n* Ocular adnexal lymphomas (OAL) originate in conjunctiva, eyelids, lacrimal gland, lacrimal drainage apparatus, and other orbital tissues surrounding the eye. This schema should not be used for secondary lymphomatous involvement of ocular adnexa or for intraocular lymphomas.\n\n**Note 3:** **The preferred histology terms in this schema are based on the 2024 WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition.**\n\n* 9590: Malignant lymphoma, NOS\n* 9591: Malignant lymphoma, non-Hodgkin, NOS\n* 9596: Mediastinal grey zone lymphoma (MGZL)\n* 9597: Primary cutaneous follicle centre lymphoma (PCFCL)\n* 9650: Classic Hodgkin lymphoma (CHL), NOS\n* 9651: Classic Hodgkin lymphoma, lymphocyte-rich (LR-cHL)\n* 9652: Classic Hodgkin lymphoma, mixed cellularity (MC-cHL)\n* 9653: Classic Hodgkin lymphoma, lymphocyte-depleted, NOS (LD-cHL)\n* 9659: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)\n* 9663: Classic Hodgkin lymphoma, nodular sclerosis, NOS (NSCHL) \n* 9673: Mantle cell lymphoma (MCL)\n* 9678: Primary effusion lymphoma (PEL)\n* 9679: Primary mediastinal large B-cell lymphoma (PBML/PMBCL)\n* 9680: Diffuse large B-cell lymphoma (DLBCL)\n* 9687: Burkitt lymphoma (BL), NOS\n* 9688: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)\n* 9689: Splenic marginal zone lymphoma (SMZL)\n* 9690 Follicular lymphoma (FL), NOS (except C700-C729, C751-C753 for 1/1/2023+)\n* 9691: Follicular lymphoma, grade 2\n* 9695: Follicular lymphoma, grade 1\n* 9698: Follicular lymphoma, grade 3\n* 9699: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)\n* 9702: Peripheral T-cell lymphoma, NOS\n* 9705: Nodal T follicular helper cell lymphoma, angioimmunoblastic type\n* 9708: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)\n* 9709: Primary cutaneous peripheral T-cell lymphomas (pcCTCL)\n* 9712: Intravascular large B-cell lymphoma (IVLBCL)\n* 9714: Anaplastic large cell lymphoma, ALK-positive (ALCL)\n* 9715: Anaplastic large cell lymphoma, ALK-negative (ALK-ALCL) (2021+ only)\n* 9716: Hepatosplenic T-cell lymphoma (HSTCL)\n* 9717: Intestinal T-cell lymphoma, NOS (ITCL-NOS)\n* 9718: Primary cutaneous anaplastic large cell lymphoma (C-ALCL)\n* 9719: Extranodal NK/T-cell lymphoma (ENKTL) (except C700-C729, C751-C753 for 1/1/2023+)\n* 9725: Hydroa vacciniforme-like lymphoma (2018-2020 only, nonreportable as of 2021)\n* 9726 Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) (2018-2020 only, see code 9687/3 for 2021+)\n* 9734: Extramedullary plasmacytoma (EMP)\n* 9735: Plasmablastic lymphoma (PBL)\n* 9737: ALK-positive large B-cell lymphoma (ALK+LBCL)\n* 9738: KSHV/HHV8-positive diffuse large B-cell lymphoma \n* 9823: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)\n* 9826: Burkitt cell leukemia (2018-2020 only, see code 9687/3 for 2021+)\n* 9827: Adult T-cell leukemia/lymphoma (ATLL)\n* 9930: Myeloid Sarcoma",
  "schema_selection_table" : "schema_selection_lymphoma_ocular_adnexa",
  "inputs" : [ {
    "key" : "year_dx",
    "name" : "Year of Diagnosis",
    "naaccr_item" : 390,
    "naaccr_xml_id" : "dateOfDiagnosis",
    "table" : "year_dx_validation",
    "used_for_staging" : false
  }, {
    "key" : "site",
    "name" : "Primary Site",
    "naaccr_item" : 400,
    "naaccr_xml_id" : "primarySite",
    "table" : "primary_site",
    "used_for_staging" : true
  }, {
    "key" : "hist",
    "name" : "Histology",
    "naaccr_item" : 522,
    "naaccr_xml_id" : "histologicTypeIcdO3",
    "table" : "histology",
    "used_for_staging" : true
  }, {
    "key" : "reporting_source",
    "name" : "Type of Reporting Source",
    "naaccr_item" : 500,
    "naaccr_xml_id" : "typeOfReportingSource",
    "table" : "type_of_reporting_source_76696",
    "used_for_staging" : false
  }, {
    "key" : "size_clin",
    "name" : "Tumor Size Clinical",
    "naaccr_item" : 752,
    "naaccr_xml_id" : "tumorSizeClinical",
    "table" : "tumor_size_clinical_60979",
    "used_for_staging" : false
  }, {
    "key" : "size_path",
    "name" : "Tumor Size Pathological",
    "naaccr_item" : 754,
    "naaccr_xml_id" : "tumorSizePathologic",
    "table" : "tumor_size_pathological_25597",
    "used_for_staging" : false
  }, {
    "key" : "size_summary",
    "name" : "Tumor Size Summary",
    "naaccr_item" : 756,
    "naaccr_xml_id" : "tumorSizeSummary",
    "default" : "999",
    "table" : "tumor_size_summary_63115",
    "used_for_staging" : false
  }, {
    "key" : "nodes_pos",
    "name" : "Regional Nodes Positive",
    "naaccr_item" : 820,
    "naaccr_xml_id" : "regionalNodesPositive",
    "default" : "99",
    "table" : "nodes_pos_fpa",
    "used_for_staging" : false
  }, {
    "key" : "nodes_exam",
    "name" : "Regional Nodes Examined",
    "naaccr_item" : 830,
    "naaccr_xml_id" : "regionalNodesExamined",
    "default" : "99",
    "table" : "nodes_exam_76029",
    "used_for_staging" : false
  }, {
    "key" : "neoadjuvant_therapy",
    "name" : "Neoadjuvant Therapy",
    "naaccr_item" : 1632,
    "naaccr_xml_id" : "neoadjuvantTherapy",
    "default" : "9",
    "table" : "neoadjuvant_therapy_37302",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "SEER_REQUIRED",
      "start" : 2021
    } ]
  }, {
    "key" : "neoadj_tx_clinical_response",
    "name" : "Neoadjuvant Therapy – Clinical Response",
    "naaccr_item" : 1633,
    "naaccr_xml_id" : "neoadjuvTherapyClinicalResponse",
    "default" : "9",
    "table" : "neoadj_tx_clinical_response_31723",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "SEER_REQUIRED",
      "start" : 2021
    } ]
  }, {
    "key" : "neoadj_tx_treatment_effect",
    "name" : "Neoadjuvant Therapy – Treatment Effect",
    "naaccr_item" : 1634,
    "naaccr_xml_id" : "neoadjuvTherapyTreatmentEffect",
    "default" : "9",
    "table" : "neoadj_tx_treatment_effect_18122",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "SEER_REQUIRED",
      "start" : 2021
    } ]
  }, {
    "key" : "eod_primary_tumor",
    "name" : "EOD Primary Tumor",
    "naaccr_item" : 772,
    "naaccr_xml_id" : "eodPrimaryTumor",
    "default" : "999",
    "table" : "extension_bez",
    "used_for_staging" : true
  }, {
    "key" : "eod_regional_nodes",
    "name" : "EOD Regional Nodes",
    "naaccr_item" : 774,
    "naaccr_xml_id" : "eodRegionalNodes",
    "default" : "999",
    "table" : "seer_regional_nodes_27397",
    "used_for_staging" : true
  }, {
    "key" : "eod_mets",
    "name" : "EOD Mets",
    "naaccr_item" : 776,
    "naaccr_xml_id" : "eodMets",
    "default" : "00",
    "table" : "seer_mets_90003",
    "used_for_staging" : true
  }, {
    "key" : "ss2018",
    "name" : "SS2018",
    "naaccr_item" : 764,
    "naaccr_xml_id" : "summaryStage2018",
    "table" : "ss2018_lymphoma_ocular_adnexa_3583",
    "used_for_staging" : false
  }, {
    "key" : "grade_clin",
    "name" : "Grade Clinical",
    "naaccr_item" : 3843,
    "naaccr_xml_id" : "gradeClinical",
    "default" : "9",
    "table" : "grade_clinical_19087",
    "used_for_staging" : true,
    "metadata" : [ {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "CCCR_REQUIRED"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  }, {
    "key" : "grade_path",
    "name" : "Grade Pathological",
    "naaccr_item" : 3844,
    "naaccr_xml_id" : "gradePathological",
    "default" : "9",
    "table" : "grade_pathological_49403",
    "used_for_staging" : true,
    "metadata" : [ {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "CCCR_REQUIRED"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  }, {
    "key" : "grade_post_therapy_clin",
    "name" : "Grade Post Therapy Clin (yc)",
    "naaccr_item" : 1068,
    "naaccr_xml_id" : "gradePostTherapyClin",
    "table" : "grade_post_therapy_clin_43459",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  }, {
    "key" : "grade_post_therapy_path",
    "name" : "Grade Post Therapy Path (yp)",
    "naaccr_item" : 3845,
    "naaccr_xml_id" : "gradePostTherapy",
    "table" : "grade_post_therapy_path_67342",
    "used_for_staging" : false,
    "metadata" : [ {
      "name" : "NPCR_REQUIRED"
    }, {
      "name" : "COC_REQUIRED"
    }, {
      "name" : "SSDI"
    }, {
      "name" : "CCCR_REQUIRED"
    }, {
      "name" : "SEER_REQUIRED"
    } ]
  } ],
  "outputs" : [ {
    "key" : "naaccr_schema_id",
    "name" : "Schema ID",
    "naaccr_item" : 3800,
    "naaccr_xml_id" : "schemaId",
    "default" : "00710"
  }, {
    "key" : "derived_version",
    "name" : "Derived Version",
    "default" : "{{ctx_alg_version}}"
  }, {
    "key" : "ss2018_derived",
    "name" : "Derived Summary Stage 2018",
    "naaccr_item" : 762,
    "naaccr_xml_id" : "derivedSummaryStage2018",
    "table" : "derived_ss2018_lymphoma_ocular_adnexa_92324",
    "default" : "9"
  }, {
    "key" : "derived_summary_grade",
    "name" : "Derived Summary Grade 2018",
    "naaccr_item" : 1975,
    "naaccr_xml_id" : "derivedSummaryGrade2018",
    "table" : "derived_grade_71063"
  } ],
  "mappings" : [ {
    "id" : "summary_stage_2018",
    "name" : "Summary Stage 2018",
    "tables" : [ {
      "id" : "combined_grade_56638",
      "inputs" : [ "grade_path", "grade_clin" ],
      "outputs" : [ "derived_summary_grade" ]
    }, {
      "id" : "extension_bez",
      "inputs" : [ "eod_primary_tumor" ],
      "outputs" : [ "ss2018_t" ]
    }, {
      "id" : "seer_regional_nodes_27397",
      "inputs" : [ "eod_regional_nodes" ],
      "outputs" : [ "ss2018_n" ]
    }, {
      "id" : "seer_mets_90003",
      "inputs" : [ "eod_mets" ],
      "outputs" : [ "ss2018_m" ]
    }, {
      "id" : "summary_stage_raa",
      "inputs" : [ "ss2018_m", "ss2018_n", "ss2018_t" ],
      "outputs" : [ "ss2018_derived" ]
    } ]
  } ],
  "involved_tables" : [ "neoadjuvant_therapy_37302", "schema_selection_lymphoma_ocular_adnexa", "summary_stage_raa", "nodes_pos_fpa", "seer_regional_nodes_27397", "neoadj_tx_clinical_response_31723", "histology", "nodes_exam_76029", "seer_mets_90003", "ss2018_lymphoma_ocular_adnexa_3583", "tumor_size_summary_63115", "combined_grade_56638", "grade_pathological_49403", "derived_ss2018_lymphoma_ocular_adnexa_92324", "extension_bez", "grade_post_therapy_clin_43459", "type_of_reporting_source_76696", "tumor_size_pathological_25597", "tumor_size_clinical_60979", "grade_post_therapy_path_67342", "neoadj_tx_treatment_effect_18122", "primary_site", "grade_clinical_19087", "derived_grade_71063", "year_dx_validation" ],
  "last_modified" : "2025-11-14T20:06:00.063Z",
  "on_invalid_input" : "CONTINUE"
}